Tirzepatide for Weight Loss Linked to Starvation Ketoacidosis in Non-Diabetic Woman
Background
Tirzepatide is a novel dual GLP-1 and GIP receptor agonist approved for managing type 2 diabetes and obesity, known for its significant efficacy in weight reduction. While generally well-tolerated, rare metabolic complications can occur, particularly in diabetic populations. This case report addresses the uncommon occurrence of starvation ketoacidosis in a non-diabetic individual using tirzepatide for weight loss, expanding our understanding of its potential adverse effects.
Results
The patient presented with symptoms consistent with severe metabolic derangement, including nausea, vomiting, and abdominal pain, ultimately leading to a diagnosis of starvation ketoacidosis. Laboratory tests revealed elevated ketone levels and significant metabolic acidosis, with a blood pH likely below 7.35. Crucially, the patient's blood glucose levels were found to be normal or only mildly elevated, confirming her non-diabetic status. > This case uniquely demonstrates the development of starvation ketoacidosis in a non-diabetic individual receiving tirzepatide for weight loss, a rare but serious adverse event not typically associated with this demographic.
Why It Matters
This case report highlights a critical, albeit rare, adverse event associated with tirzepatide use in non-diabetic individuals seeking weight loss. It underscores the importance of clinician awareness regarding the potential for starvation ketoacidosis, even in the absence of diabetes, particularly when patients experience significant appetite suppression or reduced caloric intake. Further research and pharmacovigilance are warranted to better understand the incidence and risk factors for this complication, potentially leading to updated clinical guidelines and patient education strategies for tirzepatide users.